Jennifer Green, MD: Initiating, Accessing and Adjusting Insulin for Type 2 Diabetes


The Duke expert reviews key strategies for starting and continuing care with the pivotal glycemic control agent.

Last month, diabetes experts and specialists from the Duke Health collaborated with HCPLive on a State of the Science Summit program titled, “Institutional Perspectives in Type 2 Diabetes: Contemporary Approaches to Insulin Treatment.”

The paneled presentation was led by chair Jennifer Green, MD, diabetologist and professor of medicine at Duke University Medical Center. In an interview with HCPLive, Green discussed some of the key topics of discussion at the program, including the role of insulin as a “foundation or fundamental of care in type 2 diabetes” amid an era of evolving care strategies and advancing treatment options.

“I think it’s really important to remember that people are developing type 2 diabetes at younger and younger ages, and they are living many more years with type 2 diabetes than we have seen in the past,” Green said. “And we know that the longer a person has type 2 diabetes, the greater the chances are they’re going to need insulin at least as a component of their glucose management regimen.”

Green also discussed initiating insulin treatment, and the specificity of parameters that go into such a decision for the average patient.

“Many people, by the time they are diagnosed with type 2 diabetes, have a very high hemoglobin A1C, they have symptoms related to hyperglycemia, and it is always appropriate to think of insulin therapy right off the bat for someone in that situation,” she said.

After reviewing specific cases of patients with acute illness, pregnancy or concomitant steroid treatment, Green reviewed access and cost-effective strategies for the costly drug, as well as the rationale behind treatment intensification or modification.

“I don’t think there’s a one-size-fits-all, but when you’re talking about outpatient, usual clinical care where there isn’t an urgent need to start insulin, you can always think about…incorporating insulin as part of your approach to getting that person’s control much closer to what’s optimal to them,” Green said. “But there’s really no hard and fast rule.”

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
© 2024 MJH Life Sciences

All rights reserved.